| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30082520 | HIV | ENSG00000148154.10 | protein_coding | UGCG | No | No | 7357 | Q16739 |
| TVIS30071568 | HIV | ENSG00000148154.10 | protein_coding | UGCG | No | No | 7357 | Q16739 |
| TVIS30071569 | HIV | ENSG00000148154.10 | protein_coding | UGCG | No | No | 7357 | Q16739 |
| TVIS20007828 | HPV | ENSG00000148154.10 | protein_coding | UGCG | No | No | 7357 | Q16739 |
| TVIS20032031 | HPV | ENSG00000148154.10 | protein_coding | UGCG | No | No | 7357 | Q16739 |
| TVIS44022945 | HTLV-1 | ENSG00000148154.10 | protein_coding | UGCG | No | No | 7357 | Q16739 |
| TVIS44029870 | HTLV-1 | ENSG00000148154.10 | protein_coding | UGCG | No | No | 7357 | Q16739 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | UGCG |
|---|---|
| DrugBank ID | DB00419 |
| Drug Name | Miglustat |
| Target ID | BE0000477 |
| UniProt ID | Q16739 |
| Regulation Type | inhibitor |
| PubMed IDs | 12803929; 16247743; 17603755; 17624027; 18728838; 19956552; 18221193; 14609352; 16627252; 11752352 |
| Citations | Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60.@@Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9.@@Chien YH, Lee NC, Tsai LK, Huang AC, Peng SF, Chen SJ, Hwu WL: Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis. 2007 Oct;30(5):826. Epub 2007 Jun 21.@@Treiber A, Morand O, Clozel M: The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007 Mar;37(3):298-314.@@Ficicioglu C: Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008 Apr;4(2):425-31.@@Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18.@@Pastores GM: Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement. Recent Pat CNS Drug Discov. 2006 Jan;1(1):77-82.@@McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6.@@Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M: Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica. 2006 May;91(5):703-6. Epub 2006 Apr 19.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved |
| Direct Classification | Piperidines |
| SMILES | CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO |
| Pathways | |
| PharmGKB | PA10140 |
| ChEMBL | CHEMBL1029 |
